A Bridge for Therapeutic Innovation
A bridge for therapeutic innovation
More than ever, the demand for better healthcare in Asia is high and growing.
Today, some US and European innovators have the potential to meet the challenge, but the Asian’s drug market often seems too complex for young biopharmaceutical companies.
Each individual country presents a unique set of political socioeconomic, geographical and cultural features and distinct disease profiles, regulatory issues and local competitors.
De-risk and speed-up access to Asian drug market
To successfully address this complexity, ASAJES Ventures leads the capital investment, development, market access and licensing of late-clinical stage drug candidates originated from western countries.
Founded by Dr. Chika YOSHINAGA, who has an exceptional background in venture capital, pharmaceutical business development and clinical operations in Japan and China, and Dr. Hervé BRAILLY, a French pioneer of biopharmaceutical industry, ASAJES Ventures thus offers small and mid-size biopharma a two-in-one healthcare investment fund combining tailor-made investment and clinical development operations.
A two-in-one healthcare investment fund
Clinical development operations
Time & cost-efficient regulatory and clinical strategy
Opportunity to register products in Japan and in China
Design and form optimized collaboration scheme
Lead all investments and form syndicate whenever required